Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Kenvue

Kenvue Stock Has Unusual Put Option Activity After Lower Q2 Sales and CEO Firing

Kenvue, which manufactures Band-Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO had left. Put options are showing unusually high volume today.

Barchart

Asian shares mostly decline as worries continue over Trump's tariffs

Asian shares are trading mostly lower as worries about President Donald Trump’s latest updates to his tariffs weighed on investor sentiments

The Independent UK

Tylenol-Maker Kenvue Launches Turnaround Plans. How Should You Play KVUE Stock Here?

Kenvue Inc ousted its chief executive and announced a strategic review on Monday. Jefferies says KVUE shares could rally to $27.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Tylenol parent Kenvue has a new CEO, and he has lots of work to do to mollify activist investors

The company will likely focus on off-loading smaller beauty brands.

Fortune

Is Kenvue Stock Outperforming the Nasdaq?

Despite its recent underperformance, Kenvue has outpaced the Nasdaq over the past year, and analysts remain moderately bullish on the stock’s prospects.

Barchart

Kenvue Fights to Shield Brands Like Listerine and Tylenol Amid £112m Tariff Shock

Kenvue customers are expected to be prepared for price hikes as companies that sell directly to consumers grapple with rising costs.

International Business Times UK

Are Wall Street Analysts Predicting Kenvue Stock Will Climb or Sink?

Kenvue has outpaced the broader market over the past year, and Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

2 Under-the-Radar Consumer Staples Stocks With Big Dividends

Edgewell and Kenvue are under-the-radar consumer staples stocks poised to gain as the U.S. dollar declines. Learn why they may boost your income portfolio.

MarketBeat

Is Wall Street Bullish or Bearish on Kenvue Stock?

Despite Kenvue trailing the broader market over the past year, Wall Street analysts maintain a moderately bullish outlook on the stock's potential.

Barchart

How Is Kenvue’s Stock Performance Compared to Other Consumer Defensive Stocks

With Kenvue slightly lagging behind other consumer defensive stocks over the past year, Wall Street remains cautiously optimistic about its prospects.

Barchart

Johnson & Johnson Risks UK Lawsuit Over Talc Cancer Claim

UK claimants announced Wednesday legal action against US pharmaceutical and cosmetics giant Johnson & Johnson, alleging that women diagnosed with cancers were exposed to asbestos in the company's talcum powder.

International Business Times

What’s Behind the Rally in Kenvue Stock Today?

Starboard Value is reportedly eyeing changes at KVUE as the stock underperforms the broader market.

Barchart

Kenvue Stock: Is KVUE Outperforming the Consumer Defensive Sector?

Kenvue has recently outperformed the consumer defensive sector, and Wall Street analysts are moderately bullish about the stock’s prospects.

Barchart

3 Defensive Dividend Stocks to Protect Against Pre-Election Volatility

As the U.S. presidential election nears, here are three defensive dividend-paying stocks to help shield your portfolio from pre-election volatility.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

This Dividend Aristocrat Just Had Its Best Day Ever After Earnings

This dividend aristocrat crushed Q2 earnings and issued strong guidance, and still has some fuel left in the tank for more growth.

Barchart

3 Dividend Stocks Set to Triple Your Income in the Next Decade

Looking for a lifetime of increasing dividends? Here's 3 stocks that could fit the bill.

The Independent UK

This Morning’s Dr Zoe Williams: Nobody should be smoking at home where there’s a child or pregnant mother

Quitting smoking can be extremely difficult, but there are lots of treatments options out there to help.

Barchart

What to Expect From Kenvue's Q2 2024 Earnings Report

Kenvue is all set to announce its second-quarter results this month, and analysts forecast a single-digit decline in the company’s bottom-line figure.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Kenvue Stock Underperforming the Dow?

While Kenvue's shares have notably lagged behind the Dow Jones in the past year, analysts hold a moderately bullish outlook on the stock.

Barchart

3 High-Yield Dividend Stocks to Build a Passive Income Stream

When the market pulls back, it's an opportunity to invest in high-yield dividend stocks like Kenvue, Enterprise Products Partners, and Verizon, which offer attractive yields and growth potential.

Barchart

Kenvue Stock: Is Wall Street Bullish or Bearish?

Despite Kenvue lagging behind the broader market, Wall Street analysts remain optimistic about the stock’s prospects.

The Independent UK

Stock market today: Asian shares gain after Wall Street ticks higher amid rate-cut hopes

Asian shares have mostly advanced after Wall Street ticked higher amid hopes that Japan's moves to keep interest rates easy for investors could augur similar trends in the rest of the world

StockNews.com

Johnson & Johnson (JNJ) vs. Madrigal Pharmaceuticals (MDGL): Which Pharma Stock Is a Worthier October Investment?

With an aging population worldwide, the growing prevalence of chronic diseases, new drug discoveries and rapid digital advancements, the outlook for the pharmaceutical sector remains optimistic. Pharma stocks Johnson & Johnson (JNJ) and Madrigal Pharmaceuticals (MDGL) will likely benefit from the industry’s bright prospects. But which of these stocks is…

Fortune

Generative AI is top of mind for all types of leaders, from Treasury Secretary Janet Yellen to J&J CEO Joaquin Duato

This week’s episode of Fortune‘s Leadership Next podcast features conversations from the Fortune CEO Initiative conference.

Fortune

In rare interview, J&J CEO Joaquin Duato opens up about Baby Powder cancer lawsuits and the future of Kenvue

J&J CEO Joaquin Duato's interview on Baby Powder cancer lawsuits, Kenvue, and the COVID vaccine.

1 2 3 4 5

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Verizon Communications Inc

114 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.